"meaningful use" provides a meaningful opportunity

Cancer

Volumn 120, Issue 4, 2014, Pages 464-468

  Rabius, Vance ^a   Karam Hage, Maher ^a   Blalock, Janice A ^a   Cinciripini, Paul M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTRONIC HEALTH RECORDS; HUMANS; NEOPLASMS; SMOKING CESSATION; TOBACCO USE;

EID: 84893789733     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28436     Document Type: Review

References (24)

1. Warren GW, Marshall JR, Cummings KM, et al. Automated tobacco assessment and cessation support for cancer patients. Cancer. 2014; 120: 572-579.
2. Blumenthal D, Tavenner M,. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010; 363: 501-504.
3. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: Department of Health and Human Services, US Public Health Service; 2008.
4. Rabius V,. Design and outcome of a comprehensive smoking cessation program for cancer patients. Paper presented at: Moon Shots: Connect for Global Networking, Global Academic Programs 2013 Conference; April 3, 2013; Houston, Texas.
5. Rigotti NA, Clair C, Munafo MR, Stead LF,. Interventions for smoking cessation in hospitalised patients [serial online]. Cochrane Database Syst Rev. 2012; 5: CD001837.
6. Gritz ER, Lam CY, Vidrine DJ, Fingeret MC,. Tobacco dependence and its treatment. In:, DeVita VT Jr, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2011: 529-542.
7. Peppone LJ, Mustian KM, Morrow GR, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist. 2011; 16: 1784-1792.
8. Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T,. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol. 2012; 19: 1430-1438.
9. Ostroff JS, Jacobsen PB, Moadel AB, et al. Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. Cancer. 1995; 75: 569-576.
10. Volkow ND, Wang GJ, Fowler JS, Tomasi D,. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol. 2012; 52: 321-336.
11. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T,. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2012; 11: CD000146.
12. Rose JE, Behm FM,. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. Am J Psychiatry. 2013; 170: 860-867.
13. Mills EJ, Wu P, Lockhart I, et al. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of 120 studies involving 177,390 individuals [serial online]. Tob Induc Dis. 2010; 8: 8.
14. Hughes JR, Stead LF, Lancaster T,. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031. DOI: 10.1002/14651858.CD000031.pub3. http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD000031.pub3/pdf. Accessed October 21, 2013.
15. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002; 10: 1049-1056. (Pubitemid 135688922)
16. Cahill K, Stead LF, Lancaster T,. Nicotine receptor partial agonists for smoking cessation [serial online]. Cochrane Database Syst Rev. 2008; 3: CD006103.
17. Stead LF, Lancaster T,. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD008286. DOI: 10.1002/14651858.CD008286.pub2.
18. US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline). Rockville, MD: Department of Health and Human Services; 2008.
19. Cinciripini PM, Robinson JD, Karam-Hage M, et al. The effects of varenicline and bupropion-SR plus intensive counseling on prolonged abstinence from smoking, depression, negative affect and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013; 70: 522-533.
20. Hoogendoorn M, Welsing P, Rutten-van Molken MP,. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008; 24: 51-61. (Pubitemid 351160238)
21. Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T,. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin. 2010; 26: 549-560.
22. Zimovetz EA, Wilson K, Samuel M, Beard SM,. A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. J Eval Clin Pract. 2011; 17: 288-297.
23. Anhang Price R, Stranges E, Elixhauser A,. Cancer Hospitalizations for Adults, 2009. HCUP Reports. Healthcare Cost and Utilization Project, Statistical Brief no. 125. Rockville, MD: Agency for Healthcare Research and Quality; 2012. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb125.pdf. Accessed October 9, 2013.
24. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009; 66: 1253-1262.